Spero Therapeutics Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Spero Therapeutics hat ein Gesamteigenkapital von $96.2M und eine Gesamtverschuldung von $0.0, wodurch sich der Verschuldungsgrad auf 0% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen $167.7M bzw. $71.5M. Spero Therapeutics Das EBIT des Unternehmens beträgt $27.0M, so dass der Zinsdeckungsgrad -6.3 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von $82.3M.

Wichtige Informationen

Verhältnis von Schulden zu Eigenkapital

US$0

Verschuldung

Zinsdeckungsgrad	-6.3x
Bargeld	US$82.27m
Eigenkapital	US$96.25m
Gesamtverbindlichkeiten	US$71.45m
Gesamtvermögen	US$167.70m

Jüngste Berichte zur Finanzlage

We Think Spero Therapeutics (NASDAQ:SPRO) Can Easily Afford To Drive Business Growth

Apr 05

We're A Little Worried About Spero Therapeutics' (NASDAQ:SPRO) Cash Burn Rate

Jul 04

We're Hopeful That Spero Therapeutics (NASDAQ:SPRO) Will Use Its Cash Wisely

Mar 17

Recent updates

Spero Therapeutics Delivers On Game Plan To Create Shareholder Value

Apr 23

Spero Therapeutics, Inc. (NASDAQ:SPRO) Held Back By Insufficient Growth Even After Shares Climb 27%

Mar 12

Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Jan 02

Need To Know: Analysts Just Made A Substantial Cut To Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Estimates

May 18

Spero Therapeutics, Inc. (NASDAQ:SPRO) Shares Fly 26% But Investors Aren't Buying For Growth

Apr 17

Industry Analysts Just Upgraded Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Revenue Forecasts By 40%

Apr 13

We Think Spero Therapeutics (NASDAQ:SPRO) Can Easily Afford To Drive Business Growth

Apr 05

Spero Therapeutics: The GlaxoSmithKline-Deal Changes Everything And Protects Shareholder Value

Oct 03

Spero Therapeutics, Inc.'s (NASDAQ:SPRO) CEO Compensation Looks Acceptable To Us And Here's Why

Aug 11

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: SPRODie kurzfristigen Aktiva des Unternehmens ($140.2M) übersteigen seine kurzfristigen Passiva ($41.8M).

Langfristige Verbindlichkeiten: SPRODie kurzfristigen Vermögenswerte des Unternehmens ($140.2M) übersteigen seine langfristigen Verbindlichkeiten ($29.6M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: SPRO ist schuldenfrei.

Schulden abbauen: SPRO hatte vor 5 Jahren keine Schulden.

Schuldendeckung: SPRO hat keine Schulden und muss daher nicht durch den operativen Cashflow gedeckt werden.

Zinsdeckung: SPRO hat keine Schulden, daher ist die Deckung der Zinszahlungen kein Problem.

Spero Therapeutics Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

We Think Spero Therapeutics (NASDAQ:SPRO) Can Easily Afford To Drive Business Growth

We're A Little Worried About Spero Therapeutics' (NASDAQ:SPRO) Cash Burn Rate

We're Hopeful That Spero Therapeutics (NASDAQ:SPRO) Will Use Its Cash Wisely

Recent updates

New major risk - Revenue and earnings growth

Consensus revenue estimates fall by 50%

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Spero Therapeutics, Inc. to Report Q1, 2024 Results on May 15, 2024

Investor sentiment improves as stock rises 15%

Spero Therapeutics Delivers On Game Plan To Create Shareholder Value

Spero Therapeutics, Inc., Annual General Meeting, May 29, 2024

Consensus EPS estimates fall by 24%

Spero Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Spero Therapeutics, Inc. (NASDAQ:SPRO) Held Back By Insufficient Growth Even After Shares Climb 27%

Spero Therapeutics, Inc. to Report Q4, 2023 Results on Mar 13, 2024

New minor risk - Profitability

President notifies of intention to sell stock

Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Spero Therapeutics, Inc. Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections

Forecast to breakeven in 2026

New minor risk - Shareholder dilution

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates increase by 21%, EPS downgraded

Price target increased by 18% to US$7.50

Spero Therapeutics, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Spero Therapeutics Appoints Esther Rajavelu as Chief Business Officer

Consensus estimates of losses per share improve by 10%

Chief Medical Officer recently sold US$50k worth of stock

Spero Therapeutics, Inc., Annual General Meeting, Oct 05, 2023

Consensus estimates of losses per share improve by 38%

New major risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Spero Therapeutics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Consensus revenue estimates increase by 35%

Spero Therapeutics, Inc. Announces Chief Financial Officer Changes

Need To Know: Analysts Just Made A Substantial Cut To Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Estimates

Consensus revenue estimates fall by 36%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Spero Therapeutics, Inc. to Report Q1, 2023 Results on May 11, 2023

Spero Therapeutics, Inc. (NASDAQ:SPRO) Shares Fly 26% But Investors Aren't Buying For Growth

Industry Analysts Just Upgraded Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Revenue Forecasts By 40%

Consensus revenue estimates increase by 40%

Consensus revenue estimates increase by 53%

We Think Spero Therapeutics (NASDAQ:SPRO) Can Easily Afford To Drive Business Growth

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Spero Therapeutics, Inc. Appoints Timothy Keutzer as Chief Operating Officer, Effective as of February 1, 2023

Consensus revenue estimates increase by 183%

Insufficient new directors

Spero Therapeutics, Inc. announced that it has received $8.999973 million in funding from GSK plc

Spero Therapeutics to Present Data at IDWeek 2022

Spero Therapeutics: The GlaxoSmithKline-Deal Changes Everything And Protects Shareholder Value

Spero Therapeutics, Inc. announced that it expects to receive $8.999973 million in funding from GSK plc

Spero Therapeutics Announces Appointment of Kamal Hamed as Chief Medical Officer

Spero Therapeutics appoints Kamal Hamed MD CMO

Spero Therapeutics Provides Tebipenem HBr Program Update Following Type A Meeting with the U.S. Food and Drug Administration

Spero jumps 64% as FDA clarifies future regulatory path for UTI candidate

Consensus revenue estimates increase by 69%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Spero Therapeutics GAAP EPS of -$0.87, revenue of $1.99M

Spero Therapeutics, Inc., Annual General Meeting, Sep 15, 2022

We're A Little Worried About Spero Therapeutics' (NASDAQ:SPRO) Cash Burn Rate

The Gross Law Firm Notifies Shareholders of Spero Therapeutics, Inc. of A Class Action Lawsuit

Spero Therapeutics, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration for Its New Drug Application

Pomerantz Law Firm Announces the Filing of Class Action Lawsuit Against Spero Therapeutics, Inc

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Spero Therapeutics, Inc. to Report Q1, 2022 Results on May 16, 2022

No longer forecast to breakeven

Consensus estimates of losses per share improve by 16%

Spero Therapeutics Announces New Strategic Direction Focusing on Advancing Promising Clinical-Stage Pipeline

Insufficient new directors

Consensus revenue estimates fall by 15%

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Price target decreased to US$35.80

We're Hopeful That Spero Therapeutics (NASDAQ:SPRO) Will Use Its Cash Wisely